NCT01559025View on ClinicalTrials.gov

Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus

PHASE3UnknownINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2017

Conditions
Type 1 DiabetesInsulin Dependent DiabetesJuvenile Onset Diabetes MellitusAutoimmune Diabetes
Interventions
DRUG

Vildagliptin

Vildagliptin ( Galvus 50mg twice day) during one year

Trial Locations (1)

04022-001

RECRUITING

Federal University of São Paulo, São Paulo

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Federal University of São Paulo

OTHER